Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: Results of a preliminary study

Kreuter, Alexander; Gambichler, Thilo; Avermaete, Annelies; Happe, M.; Bacharach-Bühles, Martina; Hoffmann, Klaus; Jansen, Thomas; Altmeyer, Peter; Kobyletzki, Gregor von

doi:10.1067/mjd.2002.118552

Cited by 83 publications

(72 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…52 They speculate that UVA1 irradiation is able to suppress collagen synthesis and also induce collagenase activity, which then leads to the clinically observed softening of the sclerotic skin plaques. Similarly, Spanish researchers have described the successful initial treatment of extragenital LS with oral PUVA phototherapy in a 10-year-old girl.…”

Section: Other Potential Therapiesmentioning

confidence: 99%

Paediatric vulval lichen sclerosus

Smith

Fischer

2009

Aust J Dermatology

View full text Add to dashboard Cite

Lichen sclerosus (LS) in children is uncommon; however, it is an important differential diagnosis in any pre-pubertal child presenting with chronic vulval symptoms. The long-term prognosis is unknown; however, recent data suggests that the assumption that the condition will resolve at puberty may be incorrect. Children with LS require long-term management with topical corticosteroids, which remains the treatment of choice, as well as long-term follow up. We review the current literature on paediatric vulval LS.

show abstract

Section: Other Potential Therapiesmentioning

confidence: 99%

Paediatric vulval lichen sclerosus

Smith

Fischer

2009

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…6 Although its mechanism of action is not completely understood, it appears that NVUV-B has both anti-inflammatory and immunosuppressive effects. 7 While several reports and small case series have demonstrated the effectiveness of UV-A1 therapy (340-400 nm) for extragenital LS, 5,8,9 we could find no published studies in which NBUV-B (311-313 nm) was successfully or unsuccessfully used to treat this condition. Several studies have demonstrated that both UV-A1 and NBUV-B increase matrix-metalloproteinase levels in human skin and cultured dermal fibroblasts, 9-14 which may explain the effectiveness of UV-A1 in sclerosing skin diseases.…”

Section: Commentmentioning

confidence: 62%

Progressive Extragenital Lichen Sclerosus Successfully Treated With Narrowband UV-B Phototherapy

Colbert

Chiang²,

Carlin³

et al. 2007

Arch Dermatol

View full text Add to dashboard Cite

“…The same authors subsequently described 10 patients treated with low doses of UVA1, 20 J/cm 2 , 4 times a week for 10 weeks. Evident clinical improvement took place, confirmed by HF USG patterns, and one-year observation demonstrated relapse of lesions in only two patients [63]. Literature of the subject contains also descriptions of PUVA applied topically with a cream and applications of UVA1 in lichen sclerosus in the genital regions.…”

Section: Scleroderma-like Diseasesmentioning

confidence: 90%

Role of UVA1 phototherapy in treatment of scleroderma and scleroderma-like disorders”

Osmola‐Mańkowska¹,

Dańczak‐Pazdrowska²,

Olek‐Hrab³

et al. 2012

cejoi

View full text Add to dashboard Cite

Treatment of scleroderma and scleroderma-like diseases poses a serious challenge to contemporary dermatology due to the complexity of its pathogenesis, low incidence of the diseases and their heterogenous clinical expression. the manifestation of this autoimmune disease includes an increased production and deposition of collagen fibres types I and III in the skin and connective tissue as well as vascular alterations. Ultraviolet A1 (UVA1) phototherapy affects various stages of a morbid process in scleroderma: it inhibits inflammation and affects the consequences of it, fibrosis. Currently, UVA1 is proposed as a potential treatment and is believed to have a multifold mechanism of action. This includes, inducing apoptosis in T and B lymphocytes, inhibition of proinflammatory cytokine production and ability to induce collagenase production by fibroblasts. UVA1 irradiation may also interact with endothelial cells, promoting angiogenesis. Efficacy of high, moderate, and low doses of UVA1 was documented. Advantages of UVA1 phototherapy include the evident avoidance of systemic side effects of psoralens such as nausea and vomiting or photokeratitis as well as lower risk of phototoxic reactions with deeper penetration of radiation. Its disadvantages include high cost of equipment, thus reducing the accessibility of the treatment to specialized centres. Due to its unique mechanism of action, attempts to useUVA1 phototherapy seem justified in other rare diseases, developing with skin induration.

show abstract

Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: Results of a preliminary study

Cited by 83 publications

References 20 publications

Paediatric vulval lichen sclerosus

Paediatric vulval lichen sclerosus

Progressive Extragenital Lichen Sclerosus Successfully Treated With Narrowband UV-B Phototherapy

Role of UVA1 phototherapy in treatment of scleroderma and scleroderma-like disorders”

Contact Info

Product

Resources

About